4.6 Editorial Material

Cholesterol, systemic inflammation, interleukin-1β, and osteoarthritis risk -aligning animal models with specific patient endotypes provides novel insights

Related references

Note: Only part of the references are listed.
Review Orthopedics

Structural phenotypes of knee osteoarthritis: potential clinical and research relevance

Frank W. Roemer et al.

Summary: Structural phenotypic stratification can lead to more targeted trial populations and personalized treatment recommendations for patients. Radiologists can define the risk of progression in a joint based on the predominant phenotype present at different disease stages.

SKELETAL RADIOLOGY (2023)

Article Geriatrics & Gerontology

Phenotypes in Osteoarthritis Why Do We Need Them and Where Are We At?

Murillo Dorio et al.

CLINICS IN GERIATRIC MEDICINE (2022)

Review Orthopedics

OA foundations- experimental models of osteoarthritis

S. Zaki et al.

Summary: Osteoarthritis is a disease with diverse phenotypes, and the selection and use of animal models in research should align with patient sub-types. This review discusses the importance of selecting animal models based on study objectives, alignment with sub-types, and available resources. It also proposes an experimental design checklist for choosing the optimal model.

OSTEOARTHRITIS AND CARTILAGE (2022)

Review Orthopedics

Fundamentals of OA. An initiative of Osteoarthritis and Cartilage. and metabolic factors in OA

A. Batushansky et al.

Summary: This article provides another perspective by discussing how obesity increases the risk of knee osteoarthritis by altering metabolism and inflammation. The relationship between metabolic syndrome and osteoarthritis is context-dependent, and the factors contributing to obesity-induced osteoarthritis may differ between men and women. Metabolomic analyses have identified potential diagnostic and prognostic biomarkers for knee osteoarthritis.

OSTEOARTHRITIS AND CARTILAGE (2022)

Review Pharmacology & Pharmacy

A narrative review of anti-obesity medications for obese patients with osteoarthritis

Win Min Oo et al.

Summary: This narrative review examines the association between obesity and osteoarthritis (OA) and the impact of weight loss on OA. It provides an overview of FDA-approved anti-obesity drugs and their clinical efficacy and safety profiles, as well as ongoing clinical trials of these drugs in OA patients. The review also discusses various perspectives and expert opinions related to the prescription principles of anti-obesity drugs, phenotype-guided approaches, time to drug effects, sustainability of weight loss, concomitant therapies, and the role of weight loss in non-weight bearing OA joints.

EXPERT OPINION ON PHARMACOTHERAPY (2022)

Review Immunology

Obesity, Inflammation, and Immune System in Osteoarthritis

Udhaya Nedunchezhiyan et al.

Summary: Obesity is the most important risk factor for the development and progression of osteoarthritis, and it was previously believed to be caused by excessive weight leading to joint overloading and cartilage destruction. However, recent studies have identified other factors such as adipose deposition, insulin resistance, and the improper coordination of innate and adaptive immune responses that contribute to obesity-associated osteoarthritis. Multiple inflammatory cells are recruited into the synovial joint and play an important role in pathological changes. Macrophage polarization and mediators produced by macrophages have been extensively studied and linked to the inflammatory and destructive responses in the synovium and cartilage. The role of other innate immune cells and adaptive immune cells in the pathogenesis of osteoarthritis is still under exploration.

FRONTIERS IN IMMUNOLOGY (2022)

Article Multidisciplinary Sciences

Adipose tissue is a critical regulator of osteoarthritis

Kelsey H. Collins et al.

Summary: Obesity is closely related to osteoarthritis, but the specific mechanisms by which it leads to OA are complex. Research shows that adipose tissue plays a critical role in the pathophysiology of OA, and paracrine signaling from fat may be a mediator of joint degeneration.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Review Chemistry, Medicinal

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date

Win Min Oo et al.

Summary: This review discusses the need for disease modifying drugs (DMOADs) for the management of osteoarthritis (OA), the classification of clinical phenotypes or molecular/mechanistic endotypes for targeted drug discovery, and summarizes the efficacy and safety of targeted drugs in Phase 2 and 3 clinical trials targeting cartilage-driven, bone-driven, and inflammation-driven endotypes. The reasons for failures in OA clinical trials and possible steps to overcome these barriers are also briefly presented.

DRUG DESIGN DEVELOPMENT AND THERAPY (2021)

Article Rheumatology

Intergenerational Transmission of Diet-Induced Obesity, Metabolic Imbalance, and Osteoarthritis in Mice

Natalia S. Harasymowicz et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Review Medicine, General & Internal

Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns

Francis Berenbaum et al.

POSTGRADUATE MEDICINE (2020)

Review Endocrinology & Metabolism

Bidirectional association between metabolic syndrome and osteoarthritis: a meta-analysis of observational studies

Sheng-Yao Liu et al.

DIABETOLOGY & METABOLIC SYNDROME (2020)

Review Rheumatology

Is osteoarthritis one disease or a collection of many?

Leticia A. Deveza et al.

RHEUMATOLOGY (2018)

Review Orthopedics

Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review

L. A. Deveza et al.

OSTEOARTHRITIS AND CARTILAGE (2017)

Review Rheumatology

Post-traumatic osteoarthritis: from mouse models to clinical trials

Christopher B. Little et al.

NATURE REVIEWS RHEUMATOLOGY (2013)